SCHEMBL4150436

SCHEMBL4150436

N[C@@](CS)(C(=O)O)C(CCC(=O)O)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 7/20 0.42
ENPEP Q07075 5/20 0.42
ANPEP P15144 3/20 0.42
CYP1A2 P05177 2/20 0.41
GRM8 O00222 1/20 0.41
GRM6 O15303 1/20 0.41
GRIN2D O15399 1/20 0.41
GRIN3B O60391 1/20 0.41
GSR P00390 1/20 0.41
GRIK1 P39086 1/20 0.41
GRM5 P41594 1/20 0.41
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41
GRIA3 P42263 1/20 0.41
SLC1A3 P43003 1/20 0.41
SLC1A2 P43004 1/20 0.41
SLC1A1 P43005 1/20 0.41
GRIA4 P48058 1/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2A Q12879 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27561990 0.76 FOLH1 (0.46) FOLH1ENPEPANPEPCYP1A2GRM8
SCHEMBL4155771 0.73 GRM8 (0.44) FOLH1ENPEPANPEPCYP1A2GRM8
SCHEMBL22009103 0.70 ARG1 (0.39) ENPEPCYP1A2GABRPGABRDGABRA1
SCHEMBL22009123 0.70 ARG1 (0.39) ENPEPCYP1A2GABRPGABRDGABRA1
SCHEMBL16222763 0.67 ARG1 (0.48) ENPEPCYP1A2GRM2GRM3
SCHEMBL16222693 0.67 ARG1 (0.48) ENPEPCYP1A2GRM2GRM3
SCHEMBL27935875 0.67 TET2 (0.46) FOLH1CYP1A2GRM8GRM6GRIN2D
SCHEMBL1231740 0.67 CYP1A2 (0.50) FOLH1CYP1A2GRM8GRM6GRIN2D
SCHEMBL5929523 0.67 CYP1A2 (0.45) FOLH1CYP1A2GRM8GRM6GRIN2D
Ammonia Solution, Strong SCHEMBL29572919 0.66 TET2 (0.44) FOLH1CYP1A2GRM8GRM6GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1933642-B1 SALT ENHANCING COMPOUNDS AND USE HOFMANN THOMAS FRANK (DE) 2011-12-21 EP disclosed
US-20090155440-A1 Salt Enhancing Compounds and Use GIVAUDAN SA (CH) 2009-06-18 US disclosed
EP-1933642-A1 SALT ENHANCING COMPOUNDS AND USE Thomas Frank Hofmann & Andreas Dunkel Inst. für Lebensmittelchemie (DE) 2008-06-25 EP disclosed
WO-2007042274-A1 SALT ENHANCING COMPOUNDS AND USE THOMAS FRANK HOFMANN & ANDREAS DUNKEL (DE) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090155440-A1 Salt Enhancing Compounds and Use TAS1R1, TAS2R41, TAS2R40 FOLH1 651/4885ENPEP 830/4885ANPEP 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.